Arvaya Healthcare plans ₹210 cr rights issue, swaps shares for clinic
The fundraise exceeds half the company's ₹411 cr market cap. Existing shareholders face massive dilution unless they participate.
— 1 earlier story on Arvaya Healthcare Ltd. →What's new
- Board approved rights issue up to ₹210 cr, subject to approvals
- Acquired Sushodha Institute of Gastroenterology for ₹15.49 cr via share swap
- Registered office to shift from Assam to Maharashtra
Why this matters
At over half the market cap, the rights issue will massively dilute existing holders. The small acquisition signals expansion into gastroenterology, but the real story is the ₹210 cr cash call, a bet that the company can deploy it profitably.
What we're watching
- Whether shareholders approve the rights issue and at what price
- How proceeds will be deployed: organic growth or more acquisitions
- Any financial details of the acquired gastroenterology institute
The full read
Arvaya Healthcare, a nano-cap with a market cap of ₹411 crore, is shaking up its structure. The board approved a rights issue of up to ₹210 crore (more than half its market value) alongside an acquisition of Sushodha Institute of Gastroenterology for ₹15.49 crore paid entirely in shares (38.71 lakh shares at ₹40 each). The company also plans to move its registered office from Assam to Maharashtra. For existing shareholders, the numbers are stark: a ₹210 crore dilution on a ₹411 crore market cap means the current float could be more than doubled. The acquisition itself is small, but the cash infusion, if deployed, could fund larger deals. The office move suggests a pivot to a more business-friendly state. This is a board-level signal of ambition, but the execution risk is enormous.
Questions answered
- How large is the rights issue compared to the company's size?
- At ₹210 cr, it exceeds 50% of Arvaya Healthcare's current market cap of ₹411 cr, making it a massive dilution event for existing shareholders.
- What is the acquisition and how is it funded?
- Arvaya is acquiring 100% of Sushodha Institute of Gastroenterology for ₹15.49 cr, paid entirely by issuing 38.71 lakh shares at ₹40 each.
- Why is the company moving its registered office to Maharashtra?
- The board resolved to shift the office from Assam to Maharashtra, likely for regulatory or operational convenience, though no official reason was cited.
- What are the current financials of Arvaya Healthcare?
- For the quarter ended March 2026, the company reported sales of ₹9 cr and net profit of ₹1 cr. Trailing ROE is 3.9% with zero debt.
Arvaya Healthcare Ltd.
Latest quarter · Mar 2026
Strength & growth
Story so far
All notes on BIJHANS →- 11 Jul 2026 · 2:45 PM IST Arvaya Healthcare plans ₹210 cr rights issue, swaps shares for clinic
- 5d ago Arvaya Healthcare to weigh acquisition, fundraise on July 11